Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer

Mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) is now a drugable oncogenic driver and the KRAS G12C variant responds clinically to sotorasib and adagrasib that covalently block the cysteine of the active center and inhibit downstream signaling and proliferation. Unfortunately, progression-...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamilton, Gerhard, Stickler, Sandra, Rath, Barbara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Open Exploration Publishing 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651355/
https://www.ncbi.nlm.nih.gov/pubmed/38023987
http://dx.doi.org/10.37349/etat.2023.00178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651355/
https://www.ncbi.nlm.nih.gov/pubmed/38023987
http://dx.doi.org/10.37349/etat.2023.00178

Ejemplares similares